{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:56:33Z","timestamp":1765382193073},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 57-year-old man with stage IIIB malignant melanoma of unknown primary presented for pretherapy FDG PET\/CT that demonstrated metastatic left cervical lymph node with no other site of involvement. Following left neck dissection, nivolumab was initiated. Follow-up FDG PET\/CT 3 months after initiation of nivolumab demonstrated extensive radiotracer-avid chest lymphadenopathy and multiple bone lesions. Ultrasound-guided endobronchial biopsy of the mediastinal lymph nodes demonstrated sarcoidosis.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002724","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T07:06:38Z","timestamp":1564124798000},"page":"e519-e521","source":"Crossref","is-referenced-by-count":13,"title":["Nivolumab-Associated Pulmonary and Bone Sarcoidosis in a Patient With Melanoma of Unknown Primary"],"prefix":"10.1097","volume":"44","author":[{"given":"Rima I.","family":"Tulbah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrbod S.","family":"Javadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/14737140.2015.1074862","article-title":"Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma","volume":"15","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"bib2-20230925","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","year":"2016","journal-title":"Plos One"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors","volume":"23","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","year":"2018","journal-title":"J Immunother Cancer"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","article-title":"Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis","volume":"20","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"bib6-20230925","article-title":"Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"E133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma","volume":"149","year":"2016","journal-title":"Chest"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:13:32Z","timestamp":1695618812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002724","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,25]]}}}